Neuralstem, Inc. announced that it has received approval from the Food and Drug Administration to commence a Phase II trial using NSI-566 spinal cord-derived human neural stem cells in the treatment of amyotrophic lateral sclerosis .
http://www.drugs.com/clinical_trials/neuralstem-receives-fda-approval-commence-phase-ii-stem-cell-trial-amytrophic-lateral-sclerosis-15412.html
http://www.drugs.com/clinical_trials/neuralstem-receives-fda-approval-commence-phase-ii-stem-cell-trial-amytrophic-lateral-sclerosis-15412.html
No comments:
Post a Comment